Cost-effectiveness of pneumococcal conjugate vaccination in immunocompromised adults

Vaccine

Volumn 31, Issue 37, 2013, Pages 3950-3956

  Smith, Kenneth J ^a   Nowalk, Mary Patricia ^a   Raymund, Mahlon ^a   Zimmerman, Richard K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness analysis; Immunocompromising conditions; Pneumococcal vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HERD IMMUNITY; HUMAN; IMMUNOCOMPROMISED PATIENT; LIFE EXPECTANCY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEROTYPE; SINGLE DRUG DOSE; VACCINATION;

COST-EFFECTIVENESS ANALYSIS; IMMUNOCOMPROMISING CONDITIONS; PNEUMOCOCCAL VACCINATION;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; GUIDELINES AS TOPIC; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; LIFE EXPECTANCY; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84881547453     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.06.037     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61:816-819.
2. Centers for Disease Control and Prevention Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010, 59:1102-1106.
3. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC) adult indication briefing document: Prevnar 13 2011, US Department of Health and Human Services, Food and Drug Administration, Silver Spring, MD, Available at. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm279680.pdf.
4. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362:812-822.
5. Feikin D.R., Elie C.M., Goetz M.B., Lennox J.L., Carlone G.M., Romero-Steiner S., et al. Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults. Vaccine 2001, 20:545-553.
6. Lesprit P., Pedrono G., Molina J.M., Goujard C., Girard P.M., Sarrazin N., et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS 2007, 21:2425-2434.
7. Smith K.J., Zimmerman R.K., Lin C.J., Nowalk M.P., Ko F.S., McEllistrem M.C., et al. Alternative strategies for adult pneumococcal polysaccharide vaccination: a cost-effectiveness analysis. Vaccine 2008, 26:1420-1431.
8. Breiman R.F., Keller D.W., Phelan M.A., Sniadack D.H., Stephens D.S., Rimland D., et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000, 160:2633-2638.
9. French N., Nakiyingi J., Carpenter L.M., Lugada E., Watera C., Moi K., et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000, 355:2106-2111.
10. Cohen A.L., Harrison L.H., Farley M.M., Reingold A.L., Hadler J., Schaffner W., et al. Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization. AIDS 2010, 24:2253-2262.
11. Tasslimi A., Sison E.J., Story E., Alland D., Burday M., Morrison S., et al. Disappearance of vaccine-type invasive pneumococcal disease and emergence of serotype 19A in a minority population with a high prevalence of human immunodeficiency virus and low childhood immunization rates. Clin Vaccine Immunol 2009, 16:1256-1259.
12. Rozenbaum M.H., van Hoek A.J., Fleming D., Trotter C.L., Miller E., Edmunds W.J. Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysis. BMJ 2012, 345:e6879.
13. Centers for Disease Control and Prevention Cost Effectiveness of PCV13 for a Subset of Adults with Immunocompromising Conditions 2013, Available at. http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-jun-2012/05-PCV13-Cho-Stoecker.pdf.
14. SEER age-specific cancer incidence, all sites. http://seer.cancer.gov/faststats/sites.php.
15. Harrison K.M., Song R., Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 2010, 53:124-130.
16. Smith K.J., Wateska A.R., Nowalk M.P., Raymund M., Nuorti J.P., Zimmerman R.K. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012, 307:804-812.
17. American Lung Association Trends in pneumonia and influenza morbidity and mortality 2010, http://www.lungusa.org/finding-cures/our-research/trend-reports/pi-trend-report.pdf.%202010.
18. Fry A.M., Zell E.R., Schuchat A., Butler J.C., Whitney C.G. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly. Vaccine 2002, 21:303-311.
19. Metersky M.L., Dransfield M.T., Jackson L.A. Determining the optimal pneumococcal vaccination strategy for adults: is there a role for the pneumococcal conjugate vaccine. Chest 2010, 138:486-490.
20. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180:48-58.
21. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, CD000422.
22. Simonsen L., Taylor R.J., Young-Xu Y., Haber M., May L., Klugman K.P. Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio 2011, 2011.
23. Self-reported pneumococcal vaccination coverage trends 1989-2008 among adults by age group, risk group, race/ethnicity, health-care worker status, and pregnancy status, United States 2013, National Health Interview Survey (NHIS). http://www.cdc.gov/flu/professionals/vaccination/pdf/NHIS89_08ppvvaxtrendtab.pdf.
24. Cost-effectiveness in health and medicine 1996, Oxford University Press, New York. M.R. Gold, J.E. Siegel, L.B. Russell, M.C. Weinstein (Eds.).
25. Ubel P.A., Hirth R.A., Chernew M.E., Fendrick A.M. What is the price of life and why doesn't it increase at the rate of inflation. Arch Intern Med 2003, 163:1637-1641.
26. Braithwaite R.S., Meltzer D.O., King J.T., Leslie D., Roberts M.S. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule. Med Care 2008, 46:349-356.
27. Boyd C.M., Darer J., Boult C., Fried L.P., Boult L., Wu A.W. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005, 294:716-724.
28. Braithwaite R.S., Fiellin D., Justice A.C. The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines. Med Care 2009, 47:610-617.
29. Sultan S., Conway J., Edelman D., Dudley T., Provenzale D. Colorectal cancer screening in young patients with poor health and severe comorbidity. Arch Intern Med 2006, 166:2209-2214.
30. Hak E., Grobbee D.E., Sanders E.A., Verheij T.J., Bolkenbaas M., Huijts S.M., et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008, 66:378-383.
31. Millar E.V., Watt J.P., Bronsdon M.A., Dallas J., Reid R., Santosham M., et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin Infect Dis 2008, 47:989-996.
32. Lexau C.A., Lynfield R., Danila R., Pilishvili T., Facklam R., Farley M.M., et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 2005, 294:2043-2051.
33. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
34. McEllistrem M.C., Nahm M.H. Novel Pneumococcal Serotypes 6C and 6D: anomaly or harbinger. Clin Infect Dis 2012, 55:1379-1386.
35. Weycker D., Strutton D., Edelsberg J., Sato R., Jackson L.A. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010, 28:4955-4960.
36. Jackson L.A., Benson P., Sneller V.P., Butler J.C., Thompson R.S., Chen R.T., et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999, 281:243-248.
37. Sisk J.E., Whang W., Butler J.C., Sneller V.P., Whitney C.G. Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann Int Med 2003, 138:960-968.
38. Gold M.R., Franks P., McCoy K.I., Fryback D.G. Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care 1998, 36:778-792.
39. Medicare Physician Fee Schedule Look-up (CPT 90471). year: 2006. [Accessed 16.11.10]. http://www.cms.hhs.gov/apps/pfslookup/Data.
40. CDC Vaccine Price List. http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm.
41. Healthcare Cost & Utilization Project (HCUP). http://www.ahrq.gov/data/hcup/.